PARP1 and ovarian carcinoma: The phase 3 randomized JAVELIN Ovarian PARP 100 trial (NCT03642132) [290], performed on 720 patients, analyzed the combined use of talazoparib and the anti-PD-L1 mAb avelumab as maintenance therapy following avelumab plus chemotherapy, in previously untreated epithelial ovarian cancer patients.